Biotech Buyout Bolsters Novartis Cancer Portfolio

Photo of Trey Thoelcke
By Trey Thoelcke Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Pharmaceutical giant Novartis A.G. (NYSE: NVS) announced Monday morning that it will acquire startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis’s cancer immunotherapy portfolio and could provide an entry into the race for PD-1 targeting therapies.

CoStim Pharmaceuticals is a Cambridge, Mass.-based, privately held biotechnology company that is focused on harnessing the immune system to eliminate immune-blocking signals from cancer. Novartis has been focused on chimeric antigen receptor (CAR-T) technology, so the expanded pipeline will allow a combined approach.

Mark Fishman, president of the Novartis Institutes for BioMedical Research, said in a statement:

Therapy for many types of cancers are expected to increasingly rely upon rational combinations of agents. Immunotherapy agents provide additional arrows in our quiver for such combinations.

Novartis earnings and revenue fell short of consensus expectations in the fourth quarter. The company continues to struggle to rein in costs, and it announced in early February that it would cut up to 4,000 jobs, or about 6% of its workforce. Expiring patents continue to sink sales of the best-selling drugs at many pharmaceutical companies. Patent expirations for blockbuster drugs Diovan and Zometa reduced Novartis’s top line by more than $2 billion in 2013.

There has been some recent speculation about a possible break up of Novartis. Both Merck & Co. (NYSE: MRK) and Eli Lilly & Co. (NYSE: LLY) reportedly may be interested in its animal health business.

Shares of Novartis were inactive in premarket trading Monday, after ending last week at multiyear high of $82.94. That is well above the mean price target posted by Thomson/First Call.

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618